DXCM · Dexcom Inc · Webcasts, Transcripts & Audio
$83.33
+1.94 (+2.38%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$31.08B
Shares
372.95M
Volume · Nov 13
3.01M
Avg daily vol (3M)
4.23M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Dexcom Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Dexcom Inc (DXCM), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-17
Dexcom Inc (DXCM) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-17
Dexcom Inc (DXCM) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-10-29
Dexcom Inc (DXCM) Q3 2026 Earnings Call Transcript
Confident tone
CONNECT clinical evidence
Payer access and Dexcom Direct
International growth and direct distribution
Revenue
$1.34B
▲ 11.2% YoY Diluted EPS
$0.72
▲ 2.9% YoY Gross margin
64.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-09
Dexcom Inc (DXCM) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-30
Dexcom Inc (DXCM) Q2 2026 Earnings Call Transcript
Confident tone
Type 2 non-insulin expansion and coverage
CONNECT clinical trial results
Product launches and app platform
Revenue
$1.31B
▲ 13.1% YoY Diluted EPS
$0.64
▲ 42.2% YoY Gross margin
63.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Capital Markets Day
Investor event
2026-05-14
Dexcom Inc (DXCM) May 14, 2026 Capital Markets Day
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Dexcom Inc (DXCM) Q1 2026 Earnings Call Transcript
Revenue
$1.19B
▲ 15% YoY Diluted EPS
$0.51
▲ 88.9% YoY Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
Dexcom Inc (DXCM) Q4 2025 Earnings Call Transcript
Confident tone
Stelo and over-the-counter growth
Reimbursement and covered lives
Customer experience and software innovation
Revenue
$1.26B*
▲ 13.1% YoY Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Dexcom Inc (DXCM) Q3 2025 Earnings Call Transcript
Confident tone
Type 2 non-insulin access and coverage
DexCom Smart Basal
Gross margin and 10-day to 15-day transition
Revenue
$1.21B
▲ 21.6% YoY Diluted EPS
$0.70
▲ 105.9% YoY Gross margin
60.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Dexcom Inc (DXCM) Q2 2025 Earnings Call Transcript
Confident tone
Type 2 non-insulin reimbursement expansion
Stelo over-the-counter biosensor
DME channel recovery
Revenue
$1.16B
▲ 15.2% YoY Diluted EPS
$0.45
▲ 28.6% YoY Gross margin
59.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Dexcom Inc (DXCM) Q1 2025 Earnings Call Transcript
Confident tone
Type 2 non-insulin coverage expansion
Stelo over-the-counter CGM
FDA warning letter
Revenue
$1.04B
▲ 12.5% YoY Diluted EPS
$0.27
▼ 25% YoY Gross margin
56.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-13
Dexcom Inc (DXCM) Q4 2024 Earnings Call Transcript
Confident tone
Stella over-the-counter launch
International growth and reimbursement
AI and platform partnerships
Revenue
$1.11B*
▲ 7.6% YoY Gross margin
58.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-24
Dexcom Inc (DXCM) Q3 2024 Earnings Call Transcript
Positive tone
Stelo launch and over-the-counter biosensor
Reimbursement and market access expansion
International growth and G7 / DexCom ONE+ expansion
Revenue
$994.20M
▲ 2% YoY Diluted EPS
$0.34
▲ 17.2% YoY Gross margin
59.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-25
Dexcom Inc (DXCM) Q2 2024 Earnings Call Transcript
Cautious tone
Revenue per customer and rebate dynamics
DME channel underperformance
International softness
Revenue
$1.00B
▲ 15.3% YoY Diluted EPS
$0.35
▲ 25% YoY Gross margin
62.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-25
Dexcom Inc (DXCM) Q1 2024 Earnings Call Transcript
Confident tone
Stelo over-the-counter launch
Type 2 basal and hypoglycemia unawareness adoption
U.S. commercial coverage expansion
Revenue
$921.00M
▲ 24.2% YoY Diluted EPS
$0.36
▲ 200% YoY Gross margin
61.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-08
Dexcom Inc (DXCM) Q4 2023 Earnings Call Transcript
Confident tone
Stelo product launch for type 2 non-insulin
Margin and profitability trajectory
G7 product rollout and reception
Revenue
$1.03B*
▲ 26.9% YoY Gross margin
63.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-26
Dexcom Inc (DXCM) Q3 2023 Earnings Call Transcript
Revenue
$975.00M
▲ 26.7% YoY Diluted EPS
$0.29
▲ 20.8% YoY Gross margin
63.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-27
Dexcom Inc (DXCM) Q2 2023 Earnings Call Transcript
Revenue
$871.30M
▲ 25.2% YoY Diluted EPS
$0.28
▲ 133.3% YoY Gross margin
62.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-27
Dexcom Inc (DXCM) Q1 2023 Earnings Call Transcript
Revenue
$741.50M
▲ 17.9% YoY Diluted EPS
$0.12
▼ 47.8% YoY Gross margin
62.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-09
Dexcom Inc (DXCM) Q4 2022 Earnings Call Transcript
Revenue
$815.20M*
▲ 16.8% YoY Gross margin
66.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-27
Dexcom Inc (DXCM) Q3 2022 Earnings Call Transcript
Revenue
$769.60M
▲ 18.4% YoY Diluted EPS
$0.24
▲ 14.3% YoY Gross margin
64.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-28
Dexcom Inc (DXCM) Q2 2022 Earnings Call Transcript
Revenue
$696.20M
▲ 17% YoY Diluted EPS
$0.12
▼ 36.8% YoY Gross margin
64.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-28
Dexcom Inc (DXCM) Q1 2022 Earnings Call Transcript
Revenue
$628.80M
▲ 24.5% YoY Diluted EPS
$0.23
▲ 64.3% YoY Gross margin
63.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-10
Dexcom Inc (DXCM) Q4 2021 Earnings Call Transcript
Revenue
$698.20M*
▲ 22.7% YoY Gross margin
67.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-28
Dexcom Inc (DXCM) Q3 2021 Earnings Call Transcript
Revenue
$650.20M
▲ 29.8% YoY Diluted EPS
$0.21
▲ 15.1% YoY Gross margin
68.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Dexcom Inc (DXCM) Q2 2021 Earnings Call Transcript
Revenue
$595.10M
▲ 31.7% YoY Diluted EPS
$0.19
▲ 58.3% YoY Gross margin
70.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Dexcom Inc (DXCM) Q1 2021 Earnings Call Transcript
Revenue
$505.00M
▲ 24.7% YoY Diluted EPS
$0.14
▲ 166.7% YoY Gross margin
68.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-11
Dexcom Inc (DXCM) Q4 2020 Earnings Call Transcript
Revenue
$568.90M*
▲ 22.9% YoY Gross margin
70.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-27
Dexcom Inc (DXCM) Q3 2020 Earnings Call Transcript
Revenue
$500.90M
▲ 26.4% YoY Diluted EPS
$0.18
▲ 46% YoY Gross margin
68.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-28
Dexcom Inc (DXCM) Q2 2020 Earnings Call Transcript
Revenue
$451.80M
▲ 34.3% YoY Diluted EPS
$0.12
Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-28
Dexcom Inc (DXCM) Q1 2020 Earnings Call Transcript
Revenue
$405.10M
▲ 44.4% YoY Diluted EPS
$0.05
Gross margin
63.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Dexcom Inc (DXCM) Q4 2019 Earnings Call
Revenue
$462.80M
▲ 36.9% YoY Diluted EPS
$0.25
Gross margin
66.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 webcasts
Key facts
CIK
1093557
CUSIP
252131107
13F (30d)
842 filings
771 filers
Visit website
Investor relations